Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3972406 · 1 trial · 1 indication
* The PASI is an investigator-administered, multi-item scale used to measure the severity of psoriasis based on lesion severity and the percent of body surface area (BSA) affected. * Erythema, thickness, and scaling are scored on a scale of 0 (none) to 4 (very severe) on 4 anatomical regions: head, trunk, upper limbs, lower limbs. Degree of involvement on each of the 4 anatomic regions is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement). * The sum of severity scores for erythema, thickness, and scaling is multiplied by the degree of involvement for each anatomic region, and then multiplied by a constant corresponding to the region's percent BSA (0.1, 0.3, 0.2, and 0.4 for the above 4 regions, respectively). The resultant score for each anatomic region is then summed to yield the final PASI score. It ranges from 0 to 72, with higher scores reflecting greater disease severity. * The nonresponder imputation (NRI) method was used to handle missing data.
| Arm | Type | Description |
|---|---|---|
| LY3972406 | EXPERIMENTAL | Participants received an oral dose of LY3972406 for 12 weeks. |
| Placebo | PLACEBO_COMPARATOR | Participants received an oral dose of placebo for 12 weeks. |
| Name | Type | Description |
|---|---|---|
| LY3972406 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have moderate-to-severe chronic plaque psoriasis for at least 6 months prior to baseline * Have venous access sufficient to allow for blood sampling * Are able to swallow oral medication Exclusion Criteria: * Have any other skin conditions, excluding plaque psoriasis * Have ...
LY3972406 is an investigational small molecule being studied for the treatment of moderate-to-severe plaque psoriasis in adults. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
LY3972406 is a small molecule, but its specific molecular target has not been disclosed in available information. The drug is being investigated for its potential to treat plaque psoriasis, a chronic inflammatory skin condition.
LY3972406 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
LY3972406 is in Phase 2 clinical development. A Phase 2 trial has been completed, and the drug remains investigational, meaning it has not been approved for commercial use.
LY3972406 has one completed Phase 2 clinical trial, identified as NCT06176768, which evaluated the drug in adult participants with moderate-to-severe plaque psoriasis. The trial enrolled 33 participants in the United States and was randomized, double-blind, and placebo-controlled.
No alternative names for LY3972406 have been disclosed. The drug is identified by its code name LY3972406 and is being developed solely by Eli Lilly and Company for plaque psoriasis.